RxDoctor Payments Data

Elizabeth McLaughlin, OD

Optometrist · Winchester, VANPI 1487068599

Payments from drug & device makers

$1,275in general payments, 2019–2025

Across 58 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$224
  • Alcon$206
  • AbbVie$189
  • Shire North American Group Inc$169
  • Bausch & Lomb Americas Inc.$75
  • Sun Pharmaceutical Industries Inc.$74
  • plus $339 from 11 others

What the payments were for

  • Food & beverage$1,275100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,275 in reported general payments places this provider in the 60th percentile of 1,230 optometrist providers in Virginia.

See all optometrist providers in Virginia

Medicare billing

Part B allowed, 2024
$242,064
Medicare patients
1,301
Services billed
2,685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine67$87,649
LumiganBimatoprost98$51,783
XiidraLifitegrast17$27,454
Cyclosporine30$23,706
VyzultaLatanoprostene Bunod12$6,954
Travoprost20$3,641
Latanoprost227$2,658
Prednisolone Acetate50$1,327
Brimonidine Tartrate45$588
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat29$495
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha34$452
Dorzolamide Hcl15$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$189$139,432165 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$75$34,40929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,230 optometrist providers in Virginia.

Other optometrist in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →